CBRE Group (CBRE)
(Delayed Data from NYSE)
$130.18 USD
-0.79 (-0.60%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $130.17 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$130.18 USD
-0.79 (-0.60%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $130.17 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Zacks.com featured highlights include: Seagate Technology, Best Buy, Celanese, CBRE Group and Regeneron Pharma
by Zacks Equity Research
Zacks.com featured highlights include: Seagate Technology, Best Buy, Celanese, CBRE Group and Regeneron Pharma
Here's How Simon Property (SPG) is Placed Ahead of Q3 Earnings
by Zacks Equity Research
Simon Property's (SPG) Q3 results likely to reflect the gains from continued demand recovery from the global health crisis.
CBRE Group (CBRE) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
CBRE Group's (CBRE) Q3 results reflect the benefits of diversifying and expanding its resilient business in recent years.
Top 5 High ROE Stocks to Buy as Fed Tapering Looms Large
by Supriyo Bose
Seagate Technology (STX), Best Buy (BBY), Celanese Corporation (CE), CBRE Group (CBRE), and Regeneron Pharmaceuticals (REGN) are some stocks with high ROE to buy as the Fed tapering decision is expected soon.
CBRE Group (CBRE) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
CBRE (CBRE) delivered earnings and revenue surprises of 15.83% and 1.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Why CBRE Group (CBRE) is a Top Stock for the Long-Term
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Why Earnings Season Could Be Great for CBRE Group (CBRE)
by Zacks Equity Research
CBRE Group (CBRE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here is Why Growth Investors Should Buy CBRE (CBRE) Now
by Zacks Equity Research
CBRE (CBRE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
What's in the Offing for Realogy Holdings' (RLGY) Q3 Earnings?
by Zacks Equity Research
Realogy Holdings' (RLGY) Q3 results will likely reflect the benefits from its diverse brand portfolio and healthy transaction volumes.
What's in the Offing for CBRE Group's (CBRE) Q3 Earnings?
by Zacks Equity Research
CBRE Group's (CBRE) Q3 results will likely reflect benefits from its broad diversification across property types, lines of business, geographic markets and clients, and disciplined expense management.
Why CBRE (CBRE) Could Beat Earnings Estimates Again
by Zacks Equity Research
CBRE (CBRE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CBRE (CBRE) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
CBRE (CBRE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's How Much a $1000 Investment in CBRE Group Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
CBRE Group (CBRE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
CBRE (CBRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: T. Rowe Price, Best Buy, Celanese Corp, CBRE Group and Regeneron Pharma
by Zacks Equity Research
Zacks.com featured highlights include: T. Rowe Price, Best Buy, Celanese Corp, CBRE Group and Regeneron Pharma
5 High ROE Stocks to Buy as Markets Face Intense Volatility
by Supriyo Bose
T. Rowe Price Group (TROW), Best Buy (BBY), Celanese Corporation (CE), CBRE Group (CBRE), and Regeneron Pharmaceuticals (REGN) are some of the stocks with high ROE to buy in a volatile market.
Rexford (REXR) Enhances Portfolio, Buyouts Reach $1.3B in '21
by Zacks Equity Research
The acquisitions of industrial properties in the prime in-fill Southern California markets will aid Rexford (REXR) to benefit from the healthy market fundamentals.
Why This 1 Finance Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
5 Stocks With High ROE as Markets Await Fed Tapering Outlook
by Supriyo Bose
OneMain Holdings (OMF), KLA Corporation (KLAC), Bunge Limited (BG), CBRE Group, (CBRE) and Regeneron Pharmaceuticals (REGN) are some of the stocks with high ROE to buy as markets await Fed tapering clarity.
Rexford (REXR) Boosts Portfolio, Acquisitions Reach $1.03B in 2021
by Zacks Equity Research
The acquisition of industrial properties in the prime in-fill Southern California markets will aid Rexford (REXR) to benefit from the healthy market fundamentals.
CBRE (CBRE) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
CBRE (CBRE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Looking for a Growth Stock? 3 Reasons Why CBRE (CBRE) is a Solid Choice
by Zacks Equity Research
CBRE (CBRE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Add These 4 Stocks With Remarkable Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Herc Holdings (HRI), Dillard's (DDS), CBRE Group (CBRE) and The Interpublic Group of Companies (IPG) are strong enough to meet financial obligations.
Why CBRE Group (CBRE) is a Top Stock for the Long-Term
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
5 Stocks With High ROE as Markets Stumble on Tepid Jobs Report
by Supriyo Bose
T. Rowe Price Group (TROW), KLA Corporation (KLAC), Whirlpool Corporation (WHR), CBRE Group (CBRE) and Regeneron Pharmaceuticals (REGN) are some stocks with high ROE to buy as markets slip on weak jobs report.